TTetraneuron — Series A (estimated) · €5M
Tetraneuron raised €5M, which is 83% of a planned €6M round it expected to complete in Q1 2023. The money supports preclinical work (viral vector production and primate toxicology) toward a Phase I/IIa trial of its Alzheimer's gene therapy. No investors were named and no stage was stated. The amount is the €5M closed at announcement.
Lead not disclosed
RoundSeries A (estimated)
Announced27 Dec 2022
CityMadrid
SectorHealthtech & Bio · Biotech
Source
E
The company
Investors
No investors were disclosed for this round.